Developer docs
API playgroundTry for free, no card

Search company profiles

Hyperlab

Full company profile

uuid00053tc

Namestring
Hyperlab
Legal namestring
(주)히츠
Websiteurl
hyperlab.ai
Company typeenum
Private
Founded yearint
2016
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersKuala Lumpur, Malaysia
HQ citystring
Kuala Lumpur
HQ countrystring
Malaysia
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, generative molecular design, virtual compound screening, protein structure prediction, ADMET property prediction
Industry2 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Prepackaged Software7372
Product category
AI Drug Discovery Platform
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model6 records
1Core Plan Subscription
TypeSubscription Recurring
Description

Full-featured subscription providing AI docking, ADME/T prediction, and novel molecular design. Includes 6 tokens. Priced at $3,000/month per labspace.

hyperlab.ai
2Academic Plan
TypeSubscription Recurring
Description

Core AI functionality with limited computational usage at reduced cost for academic and research institutions.

hyperlab.ai
3Custom Service Plan
TypeSubscription Recurring
Description

1:1 customized plan offering expert technical support and modular platform usage tailored to research purposes.

hyperlab.ai
4Hyper Screening X Add-on
TypeSubscription Recurring
Description

Additional subscription for accessing 11 trillion+ compound library virtual screening and synthesis ordering.

hyperlab.ai
5Hyper Screening Points
TypeUsage Based
Description

Usage-based points for virtual screening across multiple targets. $1,000 per 1,000 points, available in 5-point increments.

hyperlab.ai
6Labspace Member Add-ons
TypeSubscription Recurring
Description

Additional team members for collaboration with volume-based discounts based on member count and usage duration.

hyperlab.ai
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components1 value
Technology or R&D
Pricing details7 tiers
1Core Plan at $3,000/month with 6 tokens for full AI drug discovery capabilities
ModelSubscriptionBilling cadenceMonthly
Notes

$3,000/month per labspace. Includes Hyper ADME/T, Hyper Binding, Hyper Design, Hyper Binding Co-folding, and token-based computational usage.

hyperlab.ai
2Academic Plan with same core AI features but limited computational usage at reduced cost
ModelSubscriptionBilling cadenceMonthly
Notes

Academic institution-specific plan. Separate inquiry required for pricing. Same core functionality as Core Plan within computational limits.

hyperlab.ai
3Custom Service Plan for flexible expert support and modular functionality
ModelSubscriptionBilling cadenceMonthly
Notes

1:1 customized plan with expert technical and research service support from HyperLab team. Modular functionality allows selecting only needed features.

hyperlab.ai
4Hyper Screening X add-on for extended compound library access
ModelSubscriptionBilling cadenceMonthly
Notes

Add-on to Core Plan for 11 trillion+ virtual compound space exploration with synthesis ordering capability.

hyperlab.ai
5Hyper Screening Points at $1,000 per 1,000 points
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$1,000 per 1,000 points for virtual screening across multiple targets. Purchasable in 5-point increments.

hyperlab.ai
6Labspace Member add-on for team collaboration
ModelPer seatBilling cadenceMonthly
Notes

Additional team members for collaboration. Volume discounts apply based on member count and usage duration.

hyperlab.ai
7Free 1-week trial for new users
ModelFreemiumBilling cadencePay-as-you-go
Notes

1-week free trial period. Maximum 2 labspaces per account. Free trial plan applied to first created labspace.

hyperlab.ai
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Hyperlab is a cloud-based AI drug discovery SaaS platform that enables pharmaceutical and academic researchers to perform virtual screening over a vast compound library, generate novel synthesizable molecules via generative AI, predict drug-protein binding and ADME/T properties, and predict protein 3D structures, all within an integrated labspace workflow. The platform is sold via monthly subscription tiers (Core, Academic, Custom Service) with usage-based add-ons such as Hyper Screening Points, and is used by biotech/pharma researchers globally.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 1 million molecules screened within 24 hours
+2 more records
Product overview1 text field

Hyperlab is an AI-powered drug discovery platform structured as a core plan with modular capabilities plus specialized labspaces. The primary Small Molecule Discovery suite includes Hyper Screening, Hyper Screening X, Hyper Binding, Hyper Binding Co-Folding, Hyper Design, and Hyper ADME/T, unified through a Seamless Flow architecture. Premium features like Hyper Screening X leverage the proprietary RxnFlow generative AI (ICLR 2025) with an 11+ trillion compound library. A separate Biomedical Co-Scientist labspace, powered by the KAIST co-developed K-Fold protein structure prediction model, enables conversational research workflows for antibody and protein binder design. Subscription tiers include Academic Plan (for institutions), Core Plan ($3,000/month with 6 tokens), and Custom Service Plan (enterprise). Add-on purchases cover Hyper Screening Points and additional labspace members.

Product and service7 records
1Hyper Screening
CategoryAI Drug Discovery Software
Description

Cloud-based virtual screening module that searches through large molecular libraries to identify active substances with pharmacological potential, screening up to 1 million molecules per day. Used by pharmaceutical and biotech researchers for hit identification.

2Hyper Screening X
CategoryAI Drug Discovery Software
Description

Premium virtual screening add-on module powered by the proprietary RxnFlow generative AI, providing access to an 11+ trillion virtual compound library with custom AI training for target-specific molecules, purchasable building blocks, and an 80%+ synthesizability guarantee. Used by researchers seeking higher discovery probability and direct synthesis procurement.

3Hyper Binding
CategoryAI Drug Discovery Software
Description

Drug-protein binding prediction module that uses AI to predict binding affinity, helping researchers prioritize experiments and understand binding mechanisms. Targeted at medicinal chemists and computational biologists.

4Hyper Binding Co-Folding
CategoryAI Drug Discovery Software
Description

Advanced binding prediction that simultaneously predicts both bound and unbound protein structures to capture conformational changes during the binding process, used for more accurate binding mechanism analysis.

5Hyper Design
CategoryAI Drug Discovery Software
Description

AI-powered molecular structure design module that generates novel molecules with desired properties, employing multiple generative models including GFlowNet variants and diffusion models for structure-based drug design. Used by researchers to design novel molecular structures and understand factors that change derivative activity.

6Hyper ADME/T
CategoryAI Drug Discovery Software
Description

ADME/T prediction module that forecasts absorption, distribution, metabolism, excretion, and toxicity properties of drug candidates to optimize lead selection for pharmaceutical researchers.

7Biomedical Co-Scientist
CategoryAI Drug Discovery Software
Description

Specialized labspace for biomedical research combining chat-based literature research, molecular design, and structure verification in a single conversational workflow, powered by the K-Fold protein structure prediction model and supporting antibody and protein binder design.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

HyperLab co-developed the K-Fold biomedical foundation model with KAIST. K-Fold is a next-generation AI model for protein structure prediction that uses protein's own characteristics rather than evolutionary information (MSA). It can predict protein-ligand and nucleic acid complex structures for binding site analysis and binder/antibody design. This partnership represents a core technological foundation for HyperLab's capabilities.

Strategic tierSupportingTypeTechnology or Integration
Description

HyperLab integrates with Synple Chem's synthesis service to provide 80%+ synthesis feasibility guarantee for molecules generated by Hyper Screening X. Users can request synthesis quotes and purchase building blocks directly through the platform, enabling seamless transition from virtual screening to actual synthesis.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Pioneer in AI virtual screening of small molecules against targets, with AtomNet platform and multiple pharma partnerships. Directly comparable to HyperLab's Hyper Screening / Hyper Screening X virtual screening capability.

TypeDirect peer
Description

AI-driven drug discovery platform combining generative chemistry, target identification, and clinical development. Closest direct peer to HyperLab's end-to-end small-molecule AI workflow including generative design and virtual screening.

TypeDirect peer
Description

Physics-based and AI-augmented computational chemistry platform (LiveDesign) serving pharma R&D with molecular design, FEP+, and binding prediction. Comparable in serving the same pharma computational-chemistry buyer as HyperLab, with overlap in binding/co-folding and ADMET prediction.

TypeDirect peer
Description

AI platform for drug discovery spanning target identification, molecular design, and clinical prioritization. Comparable in delivering SaaS-style AI discovery tools to enterprise pharma R&D teams.

TypeBroad incumbent
Description

AI-driven biotech combining high-throughput wet-lab experimentation with ML models for target ID and discovery. Larger, publicly listed incumbent operating across the full discovery pipeline rather than a pure-software platform.

TypeDirect peer
Description

AI + robotics drug discovery company combining crystal-structure prediction, generative molecular design, and automated synthesis — directly mirrors HyperLab's AI-design-to-synthesis loop with Synple Chem.

TypeBroad incumbent
Description

AI generative biology company pairing zero-shot AI protein design with high-throughput wet-lab validation. Larger publicly listed player in adjacent generative-design space — relevant peer for evaluating enterprise AI-discovery business models.

8Iambic Therapeutics
TypeEmerging player
Description

AI-driven drug discovery combining physics-based models with neural networks for clinical candidate design. Early-stage but well-funded emerging player with comparable generative chemistry and ADMET prediction capability to HyperLab.

9Isomorphic Labs
TypeBroad incumbent
Description

Alphabet-owned drug discovery company building on AlphaFold for structure-based drug design and novel therapeutic development. A much larger, well-capitalized incumbent in AI protein-structure-based discovery — overlaps directly with HyperLab's K-Fold value proposition.

TypeEmerging player
Description

Generative AI platform for protein and biological molecule design with wet-lab validation. Emerging competitor focused on biologics design — adjacent to HyperLab's small-molecule focus but overlapping on generative AI methodology and pharma enterprise sales motion.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Hyperlab

AI Drug Discovery Platformhyperlab.ai

Hyperlab firmographics

Firmographics
Name
Hyperlab
Legal name
(주)히츠
Website
https://hyperlab.ai
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Hyperlab industry classification

Industry
Product category
AI Drug Discovery Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • AI drug discovery
  • Generative molecular design
  • Virtual compound screening
  • Protein structure prediction
  • ADMET property prediction

Where Hyperlab is headquartered

Location

Headquarters

HQ city
Kuala Lumpur
HQ country
Malaysia
HQ region
Asia

Offices1 record

Markets served

Hyperlab business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D

Revenue model

  1. Core Plan Subscription: Full-featured subscription providing AI docking, ADME/T prediction, and novel molecular design. Includes 6 tokens. Priced at $3,000/month per labspace.
  2. Academic Plan: Core AI functionality with limited computational usage at reduced cost for academic and research institutions.
  3. Custom Service Plan: 1:1 customized plan offering expert technical support and modular platform usage tailored to research purposes.
  4. Hyper Screening X Add-on: Additional subscription for accessing 11 trillion+ compound library virtual screening and synthesis ordering.
  5. Hyper Screening Points: Usage-based points for virtual screening across multiple targets. $1,000 per 1,000 points, available in 5-point increments.
  6. Labspace Member Add-ons: Additional team members for collaboration with volume-based discounts based on member count and usage duration.

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyCore Plan at $3,000/month with 6 tokens for full AI drug discovery capabilities
SubscriptionMonthlyAcademic Plan with same core AI features but limited computational usage at reduced cost
SubscriptionMonthlyCustom Service Plan for flexible expert support and modular functionality
SubscriptionMonthlyHyper Screening X add-on for extended compound library access
Unit PricingPay-as-you-goHyper Screening Points at $1,000 per 1,000 points
Per seatMonthlyLabspace Member add-on for team collaboration
FreemiumPay-as-you-goFree 1-week trial for new users

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Hyperlab product offering

Product offering

Core offering

Hyperlab is a cloud-based AI drug discovery SaaS platform that enables pharmaceutical and academic researchers to perform virtual screening over a vast compound library, generate novel synthesizable molecules via generative AI, predict drug-protein binding and ADME/T properties, and predict protein 3D structures, all within an integrated labspace workflow. The platform is sold via monthly subscription tiers (Core, Academic, Custom Service) with usage-based add-ons such as Hyper Screening Points, and is used by biotech/pharma researchers globally.

Product overview

Hyperlab is an AI-powered drug discovery platform structured as a core plan with modular capabilities plus specialized labspaces. The primary Small Molecule Discovery suite includes Hyper Screening, Hyper Screening X, Hyper Binding, Hyper Binding Co-Folding, Hyper Design, and Hyper ADME/T, unified through a Seamless Flow architecture. Premium features like Hyper Screening X leverage the proprietary RxnFlow generative AI (ICLR 2025) with an 11+ trillion compound library. A separate Biomedical Co-Scientist labspace, powered by the KAIST co-developed K-Fold protein structure prediction model, enables conversational research workflows for antibody and protein binder design. Subscription tiers include Academic Plan (for institutions), Core Plan ($3,000/month with 6 tokens), and Custom Service Plan (enterprise). Add-on purchases cover Hyper Screening Points and additional labspace members.

Differentiator

Problem solved

Functional benefit

Products and services

  • Hyper Screening Cloud-based virtual screening module that searches through large molecular libraries to identify active substances with pharmacological potential, screening up to 1 million molecules per day. Used by pharmaceutical and biotech researchers for hit identification.
  • Hyper Screening X Premium virtual screening add-on module powered by the proprietary RxnFlow generative AI, providing access to an 11+ trillion virtual compound library with custom AI training for target-specific molecules, purchasable building blocks, and an 80%+ synthesizability guarantee. Used by researchers seeking higher discovery probability and direct synthesis procurement.
  • Hyper Binding Drug-protein binding prediction module that uses AI to predict binding affinity, helping researchers prioritize experiments and understand binding mechanisms. Targeted at medicinal chemists and computational biologists.
  • Hyper Binding Co-Folding Advanced binding prediction that simultaneously predicts both bound and unbound protein structures to capture conformational changes during the binding process, used for more accurate binding mechanism analysis.
  • Hyper Design AI-powered molecular structure design module that generates novel molecules with desired properties, employing multiple generative models including GFlowNet variants and diffusion models for structure-based drug design. Used by researchers to design novel molecular structures and understand factors that change derivative activity.
  • Hyper ADME/T ADME/T prediction module that forecasts absorption, distribution, metabolism, excretion, and toxicity properties of drug candidates to optimize lead selection for pharmaceutical researchers.
  • Biomedical Co-Scientist Specialized labspace for biomedical research combining chat-based literature research, molecular design, and structure verification in a single conversational workflow, powered by the K-Fold protein structure prediction model and supporting antibody and protein binder design.

Quantifiable outcome

  • 1 million molecules screened within 24 hours
  • +2 more outcomes

Companies that use Hyperlab

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Hyperlab technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature10 records

Hyperlab partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and supporting.

  • KAIST (Korea Advanced Institute of Science and Technology)coreStrategic or Co-development PartnerHyperLab co-developed the K-Fold biomedical foundation model with KAIST. K-Fold is a next-generation AI model for protein structure prediction that uses protein's own characteristics rather than evolutionary information (MSA). It can predict protein-ligand and nucleic acid complex structures for binding site analysis and binder/antibody design. This partnership represents a core technological foundation for HyperLab's capabilities.
  • Synple ChemsupportingTechnology or IntegrationHyperLab integrates with Synple Chem's synthesis service to provide 80%+ synthesis feasibility guarantee for molecules generated by Hyper Screening X. Users can request synthesis quotes and purchase building blocks directly through the platform, enabling seamless transition from virtual screening to actual synthesis.

Scale indicators4 records

Recent moves4 records

Expansion highlights5 records

Hyperlab competitors and assessment

Company assessment

Direct peers

  • Atomwise: Pioneer in AI virtual screening of small molecules against targets, with AtomNet platform and multiple pharma partnerships. Directly comparable to HyperLab's Hyper Screening / Hyper Screening X virtual screening capability.
  • Insilico Medicine: AI-driven drug discovery platform combining generative chemistry, target identification, and clinical development. Closest direct peer to HyperLab's end-to-end small-molecule AI workflow including generative design and virtual screening.
  • Schrödinger: Physics-based and AI-augmented computational chemistry platform (LiveDesign) serving pharma R&D with molecular design, FEP+, and binding prediction. Comparable in serving the same pharma computational-chemistry buyer as HyperLab, with overlap in binding/co-folding and ADMET prediction.
  • BenevolentAI: AI platform for drug discovery spanning target identification, molecular design, and clinical prioritization. Comparable in delivering SaaS-style AI discovery tools to enterprise pharma R&D teams.
  • XtalPi: AI + robotics drug discovery company combining crystal-structure prediction, generative molecular design, and automated synthesis — directly mirrors HyperLab's AI-design-to-synthesis loop with Synple Chem.

Broad incumbents

  • Recursion Pharmaceuticals: AI-driven biotech combining high-throughput wet-lab experimentation with ML models for target ID and discovery. Larger, publicly listed incumbent operating across the full discovery pipeline rather than a pure-software platform.
  • Absci: AI generative biology company pairing zero-shot AI protein design with high-throughput wet-lab validation. Larger publicly listed player in adjacent generative-design space — relevant peer for evaluating enterprise AI-discovery business models.
  • Isomorphic Labs: Alphabet-owned drug discovery company building on AlphaFold for structure-based drug design and novel therapeutic development. A much larger, well-capitalized incumbent in AI protein-structure-based discovery — overlaps directly with HyperLab's K-Fold value proposition.

Emerging players

  • Iambic Therapeutics: AI-driven drug discovery combining physics-based models with neural networks for clinical candidate design. Early-stage but well-funded emerging player with comparable generative chemistry and ADMET prediction capability to HyperLab.
  • Cradle Bio: Generative AI platform for protein and biological molecule design with wet-lab validation. Emerging competitor focused on biologics design — adjacent to HyperLab's small-molecule focus but overlapping on generative AI methodology and pharma enterprise sales motion.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Hyperlab financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Hyperlab leadership team

Management profile

Number of profiles

Profiles1 record

Hyperlab funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Hyperlab M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hyperlab

What does Hyperlab do?

Hyperlab is a cloud-based AI drug discovery SaaS platform that enables pharmaceutical and academic researchers to perform virtual screening over a vast compound library, generate novel synthesizable molecules via generative AI, predict drug-protein binding and ADME/T properties, and predict protein 3D structures, all within an integrated labspace workflow. The platform is sold via monthly subscription tiers (Core, Academic, Custom Service) with usage-based add-ons such as Hyper Screening Points, and is used by biotech/pharma researchers globally.

Is Hyperlab a public or private company?

Hyperlab is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Hyperlab founded?

Hyperlab was founded in 2016. It employs 11 to 50 people.

Where is Hyperlab based?

Hyperlab is headquartered in Kuala Lumpur, Malaysia, in the Asia region.

How does Hyperlab make money?

Six revenue lines are on record. Core Plan Subscription is the primary driver. The others are academic Plan, custom Service Plan, hyper Screening X Add-on, hyper Screening Points and labspace Member Add-ons.

Who are Hyperlab's main competitors?

Direct peers on record are Atomwise, Insilico Medicine, Schrödinger, BenevolentAI and XtalPi. Broad incumbents are Recursion Pharmaceuticals, Absci and Isomorphic Labs. Emerging players are Iambic Therapeutics and Cradle Bio.

Does Hyperlab have an API?

No public API is recorded for Hyperlab.

What industry is Hyperlab in?

Hyperlab's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Digital News AsiaEverise acquires Hyperlab to inject AI into the BPO/customer service industryEverise has acquired a majority stake in Hyperlab, a Southeast Asian conversational AI company based in Malaysia, to integrate its automation solutions into Everise's business process outsourcing offerings. This acquisition aims to enhance customer service efficiency by leveraging Hyperlab’s expertise in local dialects and AI technology for major clients in the financial services and telecommunications sectors. The move follows Everise's recent strategic partnership with Microsoft to develop AI-driven contact center solutions.Digital News AsiaHyperlab aims to disrupt SEA market with chat app JustAsqHyperlab launched JustAsq, a chat app connecting users to brands and experts outside their network, in Malaysia in November. The app includes clients like Maxis and Tropicana, and Hyperlab raised US$500,000 in seed funding. It plans to focus on user acquisitions in Malaysia and Singapore over the next six months.YahooMalaysia’s Potentio partners with HYPERLAB to launch a chat app that connects talent consultants with potential hiresPotentio partnered with HYPERLAB to launch JustAsq, a chat app connecting talent consultants with potential hires. The app is being piloted in performance marketing, customer service, and CRM scenarios, with HYPERLAB hosting infrastructure in the cloud. Potentio is also building partnerships with coding schools and offering career support.Digital News AsiaMalaysian tech startup Hyperlab lands US$500K seed fundingHyperlab, a Kuala Lumpur-based tech startup, closed a US$500,000 seed round in mid-April. The company will use the funds to develop a conversational platform for companies to communicate with internal teams, customers, and partners. Cofounders cite market validation from platforms like WhatsApp and WeChat.